Regeneron Pharmaceuticals, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.61B | 3.88B | 3.75B | 3.68B | 3.03B | 3.79B | 3.72B | 3.55B |
| Cost of Goods Sold | 669.4M | 584.6M | 521.6M | 530.2M | 464.3M | 565.4M | 491.1M | 480.2M |
| Gross Profit | 2.94B | 3.30B | 3.23B | 3.15B | 2.56B | 3.22B | 3.23B | 3.07B |
| R&D Expenses | 1.65B | 1.63B | 1.56B | 1.43B | 1.34B | 1.43B | 1.33B | 1.22B |
| Operating Expenses | 2.29B | 2.42B | 2.21B | 2.07B | 1.97B | 2.23B | 2.05B | 2.00B |
| Operating Income | 642.9M | 879.9M | 1.03B | 1.08B | 591.7M | 990.2M | 1.18B | 1.07B |
| Other Income / Gains | 188.3M | 163.8M | 736.5M | 439.2M | 313.3M | -32.1M | 313.5M | 558.5M |
| Net Income | 727.2M | 844.6M | 1.46B | 1.39B | 808.7M | 917.7M | 1.34B | 1.43B |
| EPS (Diluted) | 6.99 | 8.21 | 14.09 | 13.24 | 7.58 | 8.53 | 12.40 | 13.25 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.814 | 0.849 | 0.861 | 0.856 | 0.847 | 0.851 | 0.868 | 0.865 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 647.7M | 775.0M | 657.8M | 634.2M | 633.0M | 792.2M | 714.4M | 758.8M |
| Other Expenses | 0 | 18.7M | -10.0M | 0 | 0 | 15.5M | 8.0M | 14.6M |
| Cost And Expenses | 2.96B | 3.00B | 2.73B | 2.60B | 2.44B | 2.80B | 2.54B | 2.48B |
| Interest Income | 183.5M | 193.3M | 175.1M | 174.8M | 173.5M | 183.1M | 187.4M | 179.4M |
| Interest Expense | 12.9M | 12.2M | 19.3M | 3.6M | 8.7M | 10.5M | 13.8M | 14.8M |
| Depreciation And Amortization | 123.2M | 145.0M | 136.7M | 135.1M | 126.9M | 126.4M | 121.7M | 120.7M |
| Ebitda | 967.3M | 1.20B | 1.92B | 1.66B | 1.04B | 1.09B | 1.63B | 1.76B |
| Ebitdaratio | 0.268 | 0.309 | 0.511 | 0.451 | 0.344 | 0.289 | 0.438 | 0.497 |
| Operating Income Ratio | 0.178 | 0.227 | 0.273 | 0.294 | 0.195 | 0.261 | 0.317 | 0.302 |
| Income Before Tax | 831.2M | 1.04B | 1.76B | 1.52B | 905.0M | 958.1M | 1.49B | 1.63B |
| Income Before Tax Ratio | 0.231 | 0.269 | 0.47 | 0.413 | 0.299 | 0.253 | 0.401 | 0.459 |
| Income Tax Expense | 104.0M | 199.1M | 303.3M | 127.1M | 96.3M | 40.4M | 152.4M | 195.8M |
| Net Income Ratio | 0.202 | 0.217 | 0.389 | 0.379 | 0.267 | 0.242 | 0.36 | 0.404 |
| Epsdiluted | 6.75 | 7.86 | 13.62 | 12.81 | 7.27 | 8.06 | 11.54 | 12.41 |
| Weighted Average Shs Out | 104.0M | 102.9M | 103.6M | 105.1M | 106.7M | 107.9M | 108.1M | 108.1M |
| Weighted Average Shs Out Dil | 107.7M | 107.5M | 107.2M | 108.6M | 111.2M | 113.8M | 116.2M | 115.4M |